Martinsried/Munich, July 16, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) anounces that today the Annual Shareholders’ Meeting passed all resolutions with a vast majority of shareholders. Dr. Thomas Strüngmann and Dr. Mathias Albert Boehringer were elected as new Supervisory Board members. Dr. Thomas Strüngmann, a graduate in business administration, is Managing Director Santo Holding (Deutschland) GmbH and Supervisory Board Member at Wacker Chemie AG and at Südwestbank AG. Dr. Mathias Albert Boehringer, also a graduate in business administration, is a Shareholders’ Committee Member at Boehringer Ingelheim.
Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, comments: “We are very happy that we have been able to win two persons of great significance from the pharmaceutical industry for MediGene AG. They both possess excellent knowledge of the industry, and with their comprehensive expertise they will support MediGene in the pursuit of our goal of fully exploiting the great potential of the company’s various product lines.”
This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® is a trademark of MediGene AG, this trademark is licensed in select locations only.
MediGene AG is a publicly quoted (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. Another drug candidate has just received official recommendation for marketing authorization by the EMEA. MediGene has several drug candidates in clinical development. Moreover, the company has projects in research and pre-clinical development and possesses innovative platform technologies. MediGene concentrates on researching and developing novel drugs for the treatment of cancer and autoimmune diseases.
Contact MediGene AG
E-mail: investor@medigene.com
Fax:++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Georg Dönges, Public Relations, Tel.: ++49 - 89 - 85 65 - 3317
Dr. Michael Nettersheim / Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
